Treatment of Ewing's sarcoma in the cooperative Ewing's sarcoma study group

1997 ◽  
Vol 2 (3) ◽  
pp. 180-184 ◽  
Author(s):  
Toshifumi Ozaki ◽  
Winfried Winkelmann ◽  
Normann Willich ◽  
Herbert Jürgens
Keyword(s):  
Ewing’S Sarcoma ◽  
Ewing's Sarcoma ◽  
Study Group

Ifosfamide-containing chemotherapy in Ewing's sarcoma: The Second United Kingdom Children's Cancer Study Group and the Medical Research Council Ewing's Tumor Study.

1998 ◽  
Vol 16 (11) ◽  
pp. 3628-3633 ◽  
Author(s):  
A Craft ◽  
S Cotterill ◽  
A Malcolm ◽  
D Spooner ◽  
R Grimer ◽  
...  
Keyword(s):  
United Kingdom ◽  
Survival Rate ◽  
Ewing’S Sarcoma ◽  
Ewing's Sarcoma ◽  
Study Group ◽  
Primary Tumors ◽  
Cancer Study ◽  
Tumor Study ◽  
Cancer Study Group ◽  
Ewing’S Tumor

PURPOSE To investigate the possibility that the substitution of ifosfamide for cyclophosphamide therapy for Ewing's sarcoma will improve survival over that seen in the first United Kingdom Children's Cancer Study Group (UKCCSG) Ewing's tumor study (ET-1). PATIENTS AND METHODS Between 1987 and 1993,243 patients (138 men or boys) were entered onto the study. The median age was 13.5 years (range, 1.5 to 27 years). The median follow-up was 58 months. Chemotherapy included four courses of vincristine 2 mg/m2; ifosfamide 9 g/m2; and doxorubicin 60 mg/m2 administered every 3 weeks. Treatment of the primary tumor was with surgery and/or radiotherapy followed by ifosfamide 6 g/m2; doxorubicin 60 mg/m2; and vincristine 2 mg/m2; with actinomycin D 1.5 mg/m2 substituted for doxorubicin after a total dose of 420 mg/m2. RESULTS Two hundred one patients had no metastases. One hundred eighteen patients had tumors of the axial skeleton and 125 patients had limb primary tumors. The major toxicities were hematologic and infective, but there were no toxic deaths. The overall survival rate was 62% (95% confidence interval [CI], 56 to 69) and relapse-free survival (RFS) 56% (95% CI, 49 to 62). For those with no metastases at diagnosis, the RFS rate was 62% and for those with metastases, 23%. Multivariate analysis showed age and site to have a significant effect on RFS. Pelvic sites had the worst RFS rate of 41%; other axial sites, 55%; and extremity tumors, 73%. Age younger than 10 years had an RFS rate of 86% versus 55% for older patients. The local relapse rate for axial tumors was 20% and for limb primary tumors was 2.4%. CONCLUSION The 5-year survival rate of 62% is improved compared with the 44% survival rate achieved in ET-1. This is probably caused by the use of higher doses of ifosfamide compared with relatively low doses of cyclophosphamide in ET-1.

Prognostic Factors in Ewing’s Tumor of Bone: Analysis of 975 Patients From the European Intergroup Cooperative Ewing’s Sarcoma Study Group

2000 ◽  
Vol 18 (17) ◽  
pp. 3108-3114 ◽  
Author(s):  
S.J. Cotterill ◽  
S. Ahrens ◽  
M. Paulussen ◽  
H.F. Jürgens ◽  
P.A. Voûte ◽  
...  
Keyword(s):  
Prognostic Factors ◽  
Bone Metastases ◽  
Ewing’S Sarcoma ◽  
Ewing's Sarcoma ◽  
Local Therapy ◽  
Study Group ◽  
Data Set ◽  
Pädiatrische Onkologie ◽  
Survival After Relapse ◽  
Ewing’S Tumor

PURPOSE: To further elaborate on prognostic factors for Ewing’s sarcoma of bone and to document improvements in relapse-free survival (RFS) and trends in local therapy over the study period (1977 to 1993). PATIENTS AND METHODS: A retrospective analysis was performed on a combined Gesellschaft Für Pädiatrische Onkologie und Hämatologie/Cooperative Ewing Sarcoma Study and United Kingdom Children’s Cancer Study Group/Medical Research Council data set of 975 patients registered with the respective trial offices before the current collaborative European Intergroup Cooperative Ewing’s Sarcoma Study trial. Both groups independently undertook studies with similar chemotherapy during the period. RESULTS: The key adverse prognostic factor is metastases at diagnosis (5-year RFS, 22% of patients with metastases at diagnosis v 55% of patients without metastases at diagnosis; P < .0001). For the group with metastases, there was a trend for better survival for those with lung involvement compared with those with bone metastases or a combination of lung and bone metastases (P < .0001). In the group of patients with no metastases at diagnosis, multivariate analysis demonstrated that site (axial v other), age-group (< 15 v ≥ 15 years), and period of diagnosis had significant influence on RFS (all P < .005). RFS was superior in the period after 1985 compared with the period before 1985 for nonmetastatic patients (45% v 60%, respectively; P < .0001) and for metastatic patients (16% v 30%, respectively; P = .016). Patients who relapsed within 2 years of diagnosis had a less favorable prognosis than patients who relapsed later (5-year survival after relapse, 4% v 23%, respectively; P < .0001). There were other changes over the period; in particular, radiotherapy or amputation were more common in the period before 1986, whereas endoprosthetic surgery was widely used in the later period. CONCLUSION: Survival and RFS improved over the period. Prognostic factors are metastases at diagnosis, primary site, and age.

Extraskeletal Ewing’s sarcoma presenting as a neck mass - case report

ORL ro ◽  
2017 ◽  
Vol 2 (35) ◽  
pp. 24
Author(s):  
Daniel Mirea ◽  
Loredana Mitran ◽  
Daniela Safta ◽  
Cornelia Niţipir ◽  
Bogdan Mocanu ◽  
...  
Keyword(s):  
Case Report ◽  
Ewing’S Sarcoma ◽  
Ewing's Sarcoma ◽  
Neck Mass ◽  
Extraskeletal Ewing’S Sarcoma ◽  
Mass Case
Sign in / Sign up

Export Citation Format

Share Document